As part of this shift in focus, Schwarzer stepped down as CEO, with Mary Beth Harler appointed as his replacement. Harler joined IGM in 2021 as president of autoimmunity and inflammation following an ...

The new study included 82 patients whose large B-cell lymphoma had failed to respond to treatment or had returned after a ...

Dividend investing has become increasingly popular over time, as generating regular income remains a key focus for investors.

One of the first no-brainer dividend stocks to buy with $100 right now is AT&T. At recent prices, America's second-largest ...

The US FDA has approved a new drug, Cobenfy, for treating schizophrenia in adults. This is a first new class for medication ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. in a research collaboration and license agreement totaling $3.61 billion. The two companies plan ...

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

Mavacamten had been FDA approved on the basis of the EXPLORER-HCM trial's finding that the drug resulted in better functional ...

A New York federal judge dismissed allegations on Monday that Bristol Myers Squibb purposely delayed Breyanzi’s approval to ...

In an effort to expand its cash runway beyond 12 months, Prime Medicines has signed a deal with Bristol Myers Squibb worth a ...